Member Info for Brainer

TILS has £140 millions market capital and Panitta Partner is a major share holder of TILS, but do you know Panitta Partners is the largest shareholder in OKYO too? Panitta Partners hold 47.95% of OKYO.

You decide which one to buy, OKYO has two Licences, listed in Main market not in AIM, and only £11 millions market capital, only 2.87% free float, all this institutional holders!

On 21 February 2018, the Company announced that it had identified an opportunity to obtain (via assignment from Panetta Partners Limited, a related party) a license from On Target Therapeutics LLC and a sub-licence from Tufts Medical Center Inc. of the right to exploit all of the intellectual property relating to rights claimed on patent WO2017014605, being claims in composition of matter and methodology for treating, inter alia, ocular inflammation, dry eye disease (‘‘DED’’) and ocular neuropathic pain with Chemerin or a fragment of analog thereof and a lipid entity linked to the Chemerin or fragment or analog thereof (the ‘‘Chemerin Project’’).

Now, did say strong bounce back to 4 to 5p coming

2.40p paid

TILS has £140 millions market capital and Panitta Partner is a major share holder of TILS, but do you know Panitta Partners is the largest shareholder in OKYO too? Panitta Partners hold 47.95% of OKYO.

You decide which one to buy, OKYO has two Licences, listed in Main market not in AIM, and only £11 millions market capital, only 2.87% free float, all this institutional holders!

Another 100k buy at 2.24p, I think that’s 2.25p finished, looks like a big afternoon coming

0.50p will reflect on the results

CORPORATE STRATEGY
OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc.
OKYO Pharma’s future strategy is to differentiate itself by focusing on opportunities where clinical development timelines are short. It is the intention that OKYO Pharma will work closely with its retained clinicians with a view to generating incremental value for its shareholders.

TILS has £140 millions market capital and Panitta Partner is a major share holder of TILS, but do you know Panitta Partners is the largest shareholder in OKYO too? Panitta Partners hold 47.95% of OKYO.

You decide which one to buy, OKYO has two Licences, listed in Main market not in AIM, and only £11 millions market capital, only 2.87% free float, all this institutional holders!

Cherimon and Bam 8

CHEMERIN PROJECT

‘patent WO2017014605 being claims in composition of matter and methodology for treating, inter alia, ocular inflammation, dry eye disease and ocular neuropathic pain with Chemerin or a fragment of analog thereof and a lipid entity linked to the Chemerin’

Bid at premium and ask going up too

Rest held by institutions and big players who lead this company into main market from AIM

Institutions holds 67.13% :- Panetta Partners 47.95% + regent marchentile 6.24% + James Mellon 6.09%+ rosey mining 6.85% = 67.13%

Share held in nominees account: Beaufort Nominees 22% + PLINIAN CAPITAL LIMITED 8% = 30%

Held by institutions and nominees: 67.13% + 30% = 97.13%, so free float only 2.87%!

Do your own research

Expect a sudden jump on sp

It’s blue already lol, pre-open 29% up

In February, nearing the end of its year, OKYO said it had been given the opportunity to buy a licence and sub-licence for a patent. The patent includes the use of the protein chemerin to treat eye inflammation and dryness.
"The company identified the chemerin project as an initial business opportunity and will look to make further complementary acquisitions in the future. The company wishes to differentiate itself by focusing on opportunities where clinical development timelines are short and where the management teams can benefit from the clinical development and commercialisation experience of its directors and senior management," said Acting Chairman Willy Simon.
By Anna Farley; annafarley@alliancenews.com

Baserite, what price did you pay then? 2.70p? I think you should topup first thing tomorrow mate? It’s gonna come good mate as it was for last 10 years!

Welldone guys, you guys are helping out the 2 large sellers who wants out, great charity work, keep it up! This company been dead for years.

With news on Cherimon and Bam 8 it could do 15p to 20p easy, without news it should bounce back to 4p to 5p range, I like buying stock at a level where its oversold and would bounce even without news, Okyo currently at that level imo!

I am very confident this is the bottom price, so far I have always called sp movement right for Okyo

Lol, news on Cherimon and Bam 8 anytime, okyo on Main market, only 2.87% free float, big ii investors on board for a reason. I didn’t expect to be able to buy back around 2p